The scientists found that between 2017 and 2022: Average total payments per patient increased 157% among adults without diabetes and 36% among those with diabetes Despite rising total payments, average out-of-pocket payments per patient declined 26% among adults without diabetes and 39% among those with diabetes GLP-1 use increased 643% among adults without diabetes and 230% among adults with diabetes Semaglutide became the dominant GLP-1 drug by 2022, accounting for 54% of usage among adults with diabetes and 65% among adults without diabetes The authors note that while this study only used data through 2022, Medicare and Medicaid spending on GLP-1s has continued to surge in recent years
Sure, theres diabetes regulation, the principal reason for taking semaglutide, the active ingredient in Ozempic
Highest pharmacy standards Every batch verified Expert oversight Hear from people who began peptide therapy with questions and moved forward with clarity, confidence, and clinically guided care
How Oana Health Can Help If you notice any of these concerning symptoms, help is just a few clicks away
Last year, she invested in D2C healthy food brand WickedGup, as well as agritech startup KishanKonnect